HTA Glossary

Health technology assessment (HTA)

Health technology assessment (HTA) is a structured, multidisciplinary way of judging the value of a health technology. It compares a medicine, device, diagnostic test, procedure or programme with the existing alternatives on clinical benefit, safety, cost and wider consequences, so that decisions on funding and use rest on evidence.

By HTA Course · Last reviewed

In more detail

HTA explained

An internationally agreed definition was published in 2020 by a joint task group co-chaired by representatives of INAHTA and HTAi. In that definition, HTA draws on several disciplines and applies clearly stated methods to establish what a health technology is worth, at any stage from before market entry to disinvestment. Its stated purpose is to inform decision-making that supports an equitable, efficient and high-quality health system.

The word technology is broad. It covers medicines, vaccines, medical devices, diagnostics, surgical procedures, public health programmes and ways of organising care.

HTA is carried out by bodies such as NICE in England, HAS in France, IQWiG and the G-BA in Germany and CDA-AMC in Canada. Their reports and recommendations inform decisions on reimbursement, pricing and clinical use. Assessment, which is the analysis of the evidence, is usually kept apart from appraisal, which is the judgement and decision that follow.

In the European Union, Regulation (EU) 2021/2282 has applied since 12 January 2025. It introduced joint clinical assessments at EU level, starting with new cancer medicines and advanced therapy medicinal products.

Go further

Learn HTA from A to Z

The HTA Course puts this term in context, with worked examples and interactive lessons across 15 modules and 79 self-paced lessons, and a certificate of completion.